Published in Mini Rev Med Chem on October 01, 2002
NMR-based approaches for the identification and optimization of inhibitors of protein-protein interactions. Chem Rev (2014) 0.89
Alkyne-linked 2,2-disubstituted-indolin-3-one oligomers as extended beta-strand mimetics. J Am Chem Soc (2009) 0.87
Synthesis and conformational analysis of bicyclic extended dipeptide surrogates. J Org Chem (2010) 0.78
The C terminus of the nuclear protein NuMA: phylogenetic distribution and structure. Protein Sci (2004) 0.76
MR1 presents microbial vitamin B metabolites to MAIT cells. Nature (2012) 3.71
The future of peptide-based drugs. Chem Biol Drug Des (2013) 3.41
Histone deacetylases as regulators of inflammation and immunity. Trends Immunol (2011) 2.18
Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol (2010) 2.07
Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells. J Exp Med (2013) 2.04
Proteases universally recognize beta strands in their active sites. Chem Rev (2005) 1.90
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther (2011) 1.81
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother (2006) 1.72
Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat Commun (2013) 1.61
Beta-strand mimetics. Chem Rev (2004) 1.52
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A (2007) 1.46
Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem (2009) 1.46
Single turn peptide alpha helices with exceptional stability in water. J Am Chem Soc (2005) 1.42
A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int (2003) 1.41
A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol (2003) 1.40
Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency. Proc Natl Acad Sci U S A (2010) 1.38
Protease inhibitors in the clinic. Med Chem (2005) 1.33
Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem (2004) 1.22
Cleavage of hemoglobin by hookworm cathepsin D aspartic proteases and its potential contribution to host specificity. FASEB J (2002) 1.20
A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today (2007) 1.19
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol (2010) 1.16
Toward drugs for protease-activated receptor 2 (PAR2). J Med Chem (2013) 1.12
Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol (2004) 1.11
An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J (2012) 1.11
Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol (2008) 1.10
Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem (2008) 1.10
Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res (2004) 1.09
Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem (2006) 1.09
Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res (2002) 1.08
Site-directed mutagenesis and kinetic studies of the West Nile Virus NS3 protease identify key enzyme-substrate interactions. J Biol Chem (2004) 1.06
Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr Top Med Chem (2009) 1.06
Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br J Pharmacol (2003) 1.05
Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum (2002) 1.03
Modular alpha-helical mimetics with antiviral activity against respiratory syncitial virus. J Am Chem Soc (2006) 1.02
Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol (2004) 1.01
Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther (2011) 1.01
Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol Pharmacol (2004) 1.00
Novel agonists and antagonists for human protease activated receptor 2. J Med Chem (2010) 1.00
Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2010) 0.99
Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem Rev (2005) 0.99
D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem (2003) 0.99
Lysine acetylation in obesity, diabetes and metabolic disease. Immunol Cell Biol (2011) 0.98
Update 1 of: Proteases universally recognize beta strands in their active sites. Chem Rev (2010) 0.98
C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J (2012) 0.97
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol (2011) 0.96
Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. J Biol Chem (2005) 0.95
The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. J Biol Chem (2006) 0.95
Antifibrotic activity of an inhibitor of group IIA secretory phospholipase A2 in young spontaneously hypertensive rats. J Immunol (2006) 0.95
In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res (2009) 0.94
Inflammatory responses induced by lipopolysaccharide are amplified in primary human monocytes but suppressed in macrophages by complement protein C5a. J Immunol (2013) 0.94
Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. Antimicrob Agents Chemother (2012) 0.94
Hookworm aspartic protease, Na-APR-2, cleaves human hemoglobin and serum proteins in a host-specific fashion. J Infect Dis (2003) 0.94
Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem (2006) 0.93
Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity. J Gen Virol (2008) 0.92
Comparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitors. PLoS One (2012) 0.92
Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB J (2013) 0.92
Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS One (2010) 0.92
Alpha-turn mimetics: short peptide alpha-helices composed of cyclic metallopentapeptide modules. J Am Chem Soc (2004) 0.92
Nonpeptidic ligands for peptide-activated G protein-coupled receptors. Chem Rev (2007) 0.92
Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J Med Chem (2006) 0.92
Towards histone deacetylase inhibitors as new antimalarial drugs. Curr Pharm Des (2012) 0.91
A cyclic beta-strand tripeptide with an alpha-helix like CD spectrum. Org Lett (2009) 0.91
A convergent solution-phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug. J Org Chem (2003) 0.90
Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries. J Med Chem (2004) 0.90
Consecutive cyclic pentapeptide modules form short alpha-helices that are very stable to water and denaturants. Angew Chem Int Ed Engl (2004) 0.90
An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats. Diabetes (2012) 0.90
Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages. J Biol Chem (2013) 0.89
Synthesis and structural properties of patellamide A derivatives and their copper(II) compounds. Chemistry (2002) 0.89
C5a, but not C5a-des Arg, induces upregulation of heteromer formation between complement C5a receptors C5aR and C5L2. Immunol Cell Biol (2013) 0.88
Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant West Nile virus NS3. Protein Expr Purif (2006) 0.88
Rv2969c, essential for optimal growth in Mycobacterium tuberculosis, is a DsbA-like enzyme that interacts with VKOR-derived peptides and has atypical features of DsbA-like disulfide oxidases. Acta Crystallogr D Biol Crystallogr (2013) 0.88
Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol (2011) 0.88
A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. Int Immunopharmacol (2005) 0.88
Comparative α-helicity of cyclic pentapeptides in water. Angew Chem Int Ed Engl (2014) 0.88
Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats. Bone (2006) 0.87
Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorg Med Chem Lett (2010) 0.87
An interaction between the methyltransferase and RNA dependent RNA polymerase domains of the West Nile virus NS5 protein. J Gen Virol (2013) 0.87
Update 1 of: Beta-strand mimetics. Chem Rev (2010) 0.87
Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew Chem Int Ed Engl (2014) 0.87
C5a receptor (CD88) inhibition improves hypothermia-induced neuroprotection in an in vitro ischemic model. Neuromolecular Med (2012) 0.86
Current status of short synthetic peptides as vaccines. Med Chem (2006) 0.86
A refined agonist pharmacophore for protease activated receptor 2. Bioorg Med Chem Lett (2007) 0.86
Constraining cyclic peptides to mimic protein structure motifs. Angew Chem Int Ed Engl (2014) 0.85
Metal clips that induce unstructured pentapeptides to be alpha-helical in water. J Am Chem Soc (2009) 0.85
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J Med Chem (2004) 0.84
An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation. Immunobiology (2013) 0.84
Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity. J Med Chem (2002) 0.84
Total synthesis, structure, and oral absorption of a thiazole cyclic peptide, sanguinamide A. Org Lett (2012) 0.84
Crystal structures of highly constrained substrate and hydrolysis products bound to HIV-1 protease. Implications for the catalytic mechanism. Biochemistry (2008) 0.84
Profiling the enzymatic properties and inhibition of human complement factor B. J Biol Chem (2007) 0.83
Left- and right-handed alpha-helical turns in homo- and hetero-chiral helical scaffolds. J Am Chem Soc (2009) 0.83
Selective hexapeptide agonists and antagonists for human complement C3a receptor. J Med Chem (2010) 0.82
Conformationally homogeneous cyclic tetrapeptides: useful new three-dimensional scaffolds. J Am Chem Soc (2003) 0.82
Formation of mononuclear and chloro-bridged binuclear copper(II) complexes of patellamide D, a naturally occurring cyclic peptide: influence of anion and solvent. J Inorg Biochem (2004) 0.82
Stereoelectronic effects dictate molecular conformation and biological function of heterocyclic amides. J Am Chem Soc (2014) 0.81
Peptide inhibitors of the Escherichia coli DsbA oxidative machinery essential for bacterial virulence. J Med Chem (2014) 0.81
Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases. J Pharm Pharmacol (2011) 0.81
A dual-purpose synthetic colloidal platform for protease mapping: substrate profiling for Dengue and West Nile virus proteases. Anal Biochem (2008) 0.81
Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc Natl Acad Sci U S A (2014) 0.81